Vertex moves to buy Crinetics in $10 billion endocrinology deal | iPharmaCenter

Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter

Optum Financial Adds Alegeus Platform To Deepen Consumer Health Benefits And Payments | iPharmaCenter

Myricx Bio Deal Brings Novel N‑Myristoyltransferase Inhibitor ADCs Into Novartis Portfolio | iPharmaCenter

Enhertu Gains EU Tumour‑Agnostic Approval For HER2‑Positive Metastatic Solid Tumours | iPharmaCenter

European Academy of Neurology (EAN) Congress 2026 | iPharmaCenter

ESMO Gastrointestinal Cancers Congress 2026 | iPharmaCenter

NICE Opens Access to New Immunotherapy in Cervical Cancer and First Disease‑Modifying Drug in Early Type 1 Diabetes

Hospital and Drug Costs Outpace Contributions in Germany, Raising Pressure on Pharma Pricing

CVS Pharmacy Joins Medicare GLP-1 Bridge and Scales Weight‑Loss Access Across the U.S. | iPharmaCenter

June 2026: CHMP Signals New Options in CLL, TNBC and Multiple Myeloma

Medicare GLP‑1 Bridge Program: Eligibility, Costs, and Drug Details | iPharmaCenter

Merck Advances Pipeline with Tulisokibart Phase 3 Data and EU Nod for Keytruda-Padcev | iPharmaCenter

CDSCO Approves AstraZeneca's Enhertu as New First-Line Combination for HER2-Positive Breast Cancer in India

Sanofi’s Cenrifki Wins EU Approval for Non-Relapsing Secondary Progressive MS | iPharmaCenter

Japan Approves Sanofi’s Wayrilz for Chronic Immune Thrombocytopenia Treatment | iPharmaCenter

AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Deal | iPharmaCenter

Top 10 pharmaceutical companies by revenues in 2026 | Official Figures | iPharmaCenter

China Clears Vanflyta for FLT3-ITD Positive AML, Marking a New Option in Targeted Leukemia Care | iPharmaCenter

FDA Clears Sanofi’s Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes | iPharmaCenter

European Hematology Association (EHA) 2026 Congress | iPharmaCenter

Takeda's Zasocitinib achieved over 2.5 times the PASI 100 rate of deucravacitinib in a head‑to‑head Ph3 psoriasis trial | iPharmaCenter

EU Launches Era of Centralized HTA with First Joint Clinical Assessment of Ojemda | iPharmaCenter

EULAR Annual Meeting in London, UK | 2026 | News | Updates | iPharmaCenter

American Diabetes Association (ADA) in New Orleans | iPharmaCenter

Best-Selling Cancer Drugs 2025: Top 10 by Revenue

American Society of Clinical Oncology (ASCO) Annual Meeting | Chicago | 2026

China’s Biotech Momentum Grows as Pfizer Signs Multi-Billion Dollar Deal with Innovent | iPharmaCenter

Imfinzi Secures US Approval as First Immunotherapy Combination for High-Risk NMIBC | iPharmaCenter

CVS Caremark Shakes Up GLP-1 Coverage as Zepbound Returns to the Formulary | iPharmaCenter

FDA Clears Decnupaz (pivekimab sunirine) for Adults With BPDCN | iPharmaCenter

SFDA Grants Promising Drug Status to Novo Nordisk’s Frehemgo for Hemophilia A | iPharmaCenter

Spain Explores Italy’s HTA Model to Advance EU HTA Regulation Implementation | iPharmaCenter

Brazil's ANVISA News - Dupixent approved for allergic fungal rhinosinusitis, Enhertu for mBC | iPharmaCenter

AIFA Innovative Drugs April 2026: Opdivo, Yervoy, Rybrevant, Carvykti Lead New Additions | Italy Pharma | News | iPharmaCenter

Eli Lilly Expands Infectious Disease Pipeline Through Strategic Biotech Acquisitions | iPharmaCenter

European Atherosclerosis Society (EAS) Congress | 2026 | News | Updates | iPharmaCenter

Germany Advances Pharmacy Reform with ApoVWG Law to Strengthen Rural Access and Healthcare Services

China Approves Elunate Plus Tyvyt for Second-Line Renal Cell Carcinoma | iPharmaCenter

FDA Approves Datroway as First TROP2-Directed ADC for First-Line Metastatic Triple-Negative Breast Cancer in Non-PD-1/PD-L1 Candidates

Europe’s Pharmaceutical Strategy in a Changing Global Order: Germany and France Push for Resilience and Competitiveness | iPharmaCenter

Lilly’s Retatrutide Shows Breakthrough Weight Loss in Phase 3 TRIUMPH-1 Trial  | iPharmaCenter

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

Top 10 Pharma Companies by Revenue in 2025 | iPharmaCenter

Most-Favored-Nation Drug Pricing: $733B in U.S. Savings? | iPharmaCenter

American Thoracic Society (ATS) International Conference in Orlando | FL | iPharmaCenter

Baxfendy (baxdrostat) Approved in the US as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension | iPharmaCenter

American Urological Association Annual Meeting 2026 | News | Updates | iPharmaCenter

BeOne Medicines’ Beqalzi (sonrotoclax) Gets FDA Approval as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma | iPharmaCenter

AstraZeneca Introduces K+ Connect Program Across India for Hyperkalemia Management